The company’s consolidated earnings before interest, tax, depreciation, and amortisation (Ebitda) margin remained stable at 20.5 per cent in Q3FY20. Ebitda (before forex and other income) grew 11.2 per cent YoY at Rs 1,208 crore. Profit after tax (PAT); however, it declined 1 per cent YoY to Rs 705 crore, due to higher depreciation.
The company said it has received final approval for four abbreviated new drug application (ANDAs) and tentative approval for 1 ANDA from US Food and Drug Administration (USFDA). The management is committed to resolve all pending regulatory issues and continuously improve quality, it added.
Meanwhile, the board has approved second interim dividend at 175 per cent i.e., Rs 1.75 per equity share of Re 1 for the financial year FY19-20.